Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke
JAMA · 2023
DOI: 10.1001/jama.2023.8073 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA, 2023. Verfasst von Brian Mac Grory und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Duke University School of Medicine, Durham, North Carolina. Hauptthemen laut MEDLINE: Brain Ischemia, Endovascular Procedures, Intracranial Hemorrhages, Ischemic Stroke. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Themen: Schlaganfall
Abstract (Originalsprache)
Importance Use of oral vitamin K antagonists (VKAs) may place patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke caused by large vessel occlusion at increased risk of complications.
Objective
To determine the association between recent use of a VKA and outcomes among patients selected to undergo EVT in clinical practice. Design, Setting, and Participants Retrospective, observational cohort study based on the American Heart Association’s Get With the Guidelines–Stroke Program between October 2015 and March 2020. From 594 participating hospitals in the US, 32 715 patients with acute ischemic stroke selected to undergo EVT within 6 hours of time last known to be well were included. Exposure VKA use within the 7 days prior to hospital arrival. Main Outcome and Measures The primary end point was symptomatic intracranial hemorrhage (sICH). Secondary end points included life-threatening systemic hemorrhage, another serious complication, any complications of reperfusion therapy, in-hospital mortality, and in-hospital mortality or discharge to hospice.
Results
Of 32 715 patients (median age, 72 years; 50.7% female), 3087 (9.4%) had used a VKA (median international normalized ratio [INR], 1.5 [IQR, 1.2-1.9]) and 29 628 had not used a VKA prior to hospital presentation. Overall, prior VKA use was not significantly associated with an increased risk of sICH (211/3087 patients [6.8%] taking a VKA compared with 1904/29 628 patients [6.4%] not taking a VKA; adjusted odds ratio [OR], 1.12 [95% CI, 0.94-1.35]; adjusted risk difference, 0.69% [95% CI, −0.39% to 1.77%]). Among 830 patients taking a VKA with an INR greater than 1.7, sICH risk was significantly higher than in those not taking a VKA (8.3% vs 6.4%; adjusted OR, 1.88 [95% CI, 1.33-2.65]; adjusted risk difference, 4.03% [95% CI, 1.53%-6.53%]), while those with an INR of 1.7 or lower (n = 1585) had no significant difference in the risk of sICH (6.7% vs 6.4%; adjusted OR, 1.24 [95% CI, 0.87-1.76]; adjusted risk difference, 1.13% [95% CI, −0.79% to 3.04%]). Of 5 prespecified secondary end points, none showed a significant difference across VKA-exposed vs VKA-unexposed groups. Conclusions and Relevance Among patients with acute ischemic stroke selected to receive EVT, VKA use within the preceding 7 days was not associated with a significantly increased risk of sICH overall. However, recent VKA use with a presenting INR greater than 1.7 was associated with a significantly increased risk of sICH compared with no use of anticoagulants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Duke University School of Medicine, Durham, North Carolina.
- Duke Clinical Research Institute, Durham, North Carolina.
- Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
- Department of Neurology, USC Keck School of Medicine, Los Angeles, California.
- Department of Neurology, Peter C. Fung, MD, Stroke Center, El Camino Hospital, Mountain View, California.
- Department of Neurology, Medical University of South Carolina, Charleston.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Mac Grory, B., Holmes, D. N., Matsouaka, R. A., Shah, S., Chang, C. W. J., Rison, R., Jindal, J., Holmstedt, C., Logan, W. R., Corral, C., Mackey, J. S., Gee, J. R., Bonovich, D., Walker, J., Gropen, T., Benesch, C., Dissin, J., Pandey, H., Wang, D., …, & Xian, Y. (2023). Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke. JAMA. https://doi.org/10.1001/jama.2023.8073
Vancouver
Mac Grory B, Holmes DN, Matsouaka RA, Shah S, Chang CWJ, Rison R, et al. Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke. JAMA. 2023. doi:10.1001/jama.2023.8073
BibTeX
@article{MacGrory2023,
author = {Mac Grory, Brian and Holmes, DaJuanicia N and Matsouaka, Roland A and Shah, Shreyansh and Chang, Cherylee W J and Rison, Richard and Jindal, Jenelle and Holmstedt, Christine and Logan, William R and Corral, Candy and Mackey, Jason S and Gee, Joey R and Bonovich, David and Walker, James and Gropen, Toby and Benesch, Curtis and Dissin, Jonathan and Pandey, Hemant and Wang, David and Unverdorben, Martin and Hernandez, Adrian F and Reeves, Mathew and Smith, Eric E and Schwamm, Lee H and Bhatt, Deepak L and Saver, Jeffrey L and Fonarow, Gregg C and Peterson, Eric D and Xian, Ying},
title = {Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.8073}
}
EUVIMED